Five Prime Therapeutics (NASDAQ:FPRX) released its quarterly earnings results on Tuesday. The biotechnology company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.22), Fidelity Earnings reports. The company had revenue of $5.77 million during the quarter, compared to the consensus estimate of $7.45 million. Five Prime Therapeutics had a negative net margin of 206.02% and a negative return on equity of 40.61%.
NASDAQ:FPRX traded down $0.98 during trading hours on Wednesday, hitting $11.13. The company had a trading volume of 979,788 shares, compared to its average volume of 423,288. The stock has a market cap of $456.48 million, a P/E ratio of -2.07 and a beta of 3.23. Five Prime Therapeutics has a 52 week low of $10.35 and a 52 week high of $33.10.
FPRX has been the topic of several recent analyst reports. BidaskClub cut shares of Five Prime Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 26th. ValuEngine cut shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, July 28th. Wells Fargo & Co cut their price target on shares of Five Prime Therapeutics from $58.00 to $35.00 and set an “outperform” rating on the stock in a report on Thursday, August 9th. Wedbush lifted their price target on shares of Five Prime Therapeutics from $17.00 to $19.00 and gave the company a “hold” rating in a report on Friday, August 10th. Finally, Citigroup cut their price target on shares of Five Prime Therapeutics from $60.00 to $44.00 and set a “buy” rating on the stock in a report on Monday, August 20th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $29.67.
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.
See Also: Diversification Important in Investing
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.